Quantification of Tau-1 showed a 40 % decrease in Tau-1 immunoreactivity in AD compared to control brain, indicating increased phosphorylation of S199/S202 tau in AD, as expected [21] (Fig. 4a; p < 0.01). The gene discussed is MAPT; the disease is Alzheimer disease.